Related Experiment Videos
CODE chemotherapy with and without granulocyte colony-stimulating factor in small-cell lung cancer
M Fukuoka1, N Masuda, S Negoro
1Department of Internal Medicine, Osaka Prefectural Habikino Hospital, Japan.
British Journal of Cancer
|January 1, 1997
Abstract:
Sixty-three patients with extensive-stage small-cell lung cancer were randomized to receive either cyclophosphamide, vincristine, doxorubicin and etoposide (CODE) alone or CODE plus recombinant human granulocyte colony-stimulating factor (rhG-CSF). rhG-CSF administration in support of CODE chemotherapy resulted in increased mean total received dose intensity for all drugs (P = 0.03) with a significant improvement in survival (P = 0.004).